Ophiomics

Building a better future for cancer patients

Developing tools for early cancer detection and selection of the best curative treatments.

Ophiomics- Precision Medicine

Ophiomics is an ISO 13485 and ISO 9001 certified, clinical-stage Medtech company developing cutting-edge diagnostic products and services integrating bioinformatics, artificial intelligence and genomics in support of diagnostic, prognostic, treatment selection and clinical follow-up in oncology.

Vision

We are committed to revolutionizing cancer diagnostics worldwide by leveraging the power of AI-driven IVD tests. We’re forging close partnerships with clinicians to develop a cutting-edge portfolio of technology-driven, cost-effective products with a massive global impact, significantly enhancing health outcomes. Our vision: to lead the world in cancer diagnostics and transform the future of healthcare.

Actionable

We create practical tools to empower clinicians’ decisions at crucial stages in the cancer patient journey, where preventative or curative interventions are possible.

Novel

We leverage the power of genomics and Machine Learning to discover novel biomarkers that address unmet clinical needs.

Integrative

We integrate biomarkers and clinical variables through cutting-edge machine-learning algorithms, creating solutions to support clinicians’ decisions.

Accessible

Our end-products – IVD medical devices – are designed to seamlessly integrate into routine clinical practice, ensuring accessibility and ease of adoption

Collaborative

We value partnerships with clinicians, academia, patients, and companies, to build upon and advance our approaches, seeking improved outcomes for all.

Leadership

Executive team

Jose Leal, PhD (CEO)

José Pereira Leal, PhD, is a bioinformatician with close to 30 years professional experience. Dr. José Pereira-Leal has a PhD in Biomedical Sciences from the University of Oporto (Portugal), having performed all the thesis research work at the Imperial College School o Medicine (London, UK) and the Souwestern Medical School at Dallas (Texas, USA). His PhD thesis focused on the biochemistry and bioinformatics of proteins involved in genetic diseases.

Joana Vaz, PhD (CSO)

Joana Cardoso Vaz, PhD, is a specialist in cancer Genomics, with ample experience collaborating with clinicians, from biomarker discovery to clinical diagnosis. Dr. Joana Cardoso Vaz has an MSc in Human Genetics from the School of Medicine of the University of Lisbon (Portugal), and a PhD in Biomedical Sciences from the University of Leiden (Netherlands). During her PhD research she specialised in cancer genomics, with a focus on colo-rectal cancer. As a post doctoral fellow she worked at the Instituto de Medicina Molecular and at the Instituto Gulbenkian de Ciência using genomics technologies (NGS, microarrays, qPCR) to study mechanism and markers of cancer progression (Breast, Liver and Oesophageal Cancer).

Leadership

Board of Directors

Leadership

Advisors

Christophe Duvoux

Hepatology - FR

Marina Berenger

Hepatology - ES

Hugo Pinto Marques

HepatoBiliary Surgery - PT

Susana Mão de Ferro

GastroEnterology - PT

Ana Sofia Carvalho

Ethics - PT

Jean-Pierre Hermet

In Vitro Diagnostics - FR

Our history

Ophiomics was founded in 2015 by José Pereira Leal and Joana Cardoso Vaz. Initially it was a clinical testing laboratory focused in oncology, that pioneered, in collaboration with Centro de Medicina Laboratorial Germano de Sousa, the routine somatic sequencing, liquid biopsies, and high throughput sequencing for cancer genetics in Portugal. The yearn to pursue innovation by both founders led to the development of a new biomarker-based algorithm to stratify liver cancer patients for curative-intent liver transplantation in collaboration with the transplant surgeon Hugo Pinto Marques. This paved the way for the launch of Ophiomics (2.0) - a company focused on developing innovative AI-assisted In Vitro Diagnostics Medical Devices - funded by the first generation of the ultra-competitive EIC Accelerator grants. Two and a half years later, we launched ou first product, HepatoPredict. This was just the beginning!

Ophiomics

Precision Medicine

The name “Ophiomics” reflects our origins and the cutting-edge technology we develop to advance the medical field. “OPHI” is inspired by the ancient Greek word for serpent, a known symbol for medicine, and by the name of the region where our company was born, Ophiussa, the mythical name for the region where modern-day Portugal is located. The suffix “OMICS” embodies our focus on data analysis and high-throughput technologies, like genomics and transcriptomics.